{
}
Analysts have made several notable recommendations, including JP Morgan maintaining an Underweight rating for Adecco with a reduced target of CHF 19.60, while Air France-KLM was downgraded by Barclays to Underweight with a target of EUR 7. ArgenX received a buy rating from HC Wainwright & Co, raising its target to 717 USD, and BioMérieux was upgraded to Outperform by Oddo BHF with a target of EUR 132. Other significant changes include upgrades for Deliveroo and Orange, while OVH Groupe remains a sell with a raised target of EUR 8.50.
UBS maintains a Buy rating on Novo Nordisk with a target price of DKK 750, indicating a 19% upside potential. Despite disruptions in Wegovy's start-up doses due to the holiday season, growth is expected to accelerate soon. Analysts view Novo as a compelling growth story in the EU pharma sector, now reasonably valued.
UBS analyst Jo Walton upgraded Novo Nordisk from a Sell to a Buy rating, adjusting the price target to DKK750.00 from DKK1,100.00, citing expectations for increased demand for GLP-1 medications. Despite slower growth in prescriptions, Walton remains optimistic about the company's prospects, particularly with the anticipated demand surge in early 2025 and the potential of CagriSema as an effective treatment for obesity and type-2 diabetes.
Novo Nordisk's shares plummeted over 21% following disappointing results from the Phase 3 trial of its obesity drug CagriSema, which achieved a 22.7% average weight reduction, falling short of the expected 25%. Analysts have reacted with downgrades, citing safety concerns and underperformance compared to competitors. Despite achieving primary study objectives, the market's response reflects significant investor disappointment.
UBS has maintained a "Neutral" rating for Novo Nordisk, setting a target price of 1,100 Danish crowns. Analyst Jo Walton highlighted disappointing results for the weight loss drug Cagrisema, which showed a 20.4% reduction, falling short of the expected 25%. Future focus may shift towards availability, tolerability, and convenience of oral administration rather than efficacy.
UBS has lowered its target price for Novonesis A/S to DKK 455 while maintaining a neutral rating. The company, a leader in enzyme and microorganism production, generates net sales primarily from cleaning products (28.5%), bioenergy (24.8%), and the food industry (22.1%), with significant revenue from North America (33.9%) and Europe/Middle East/Africa (33.5%).
UBS has lowered the target price for Novonesis A/S to DKK 455, maintaining a neutral stance on the company. As a leading producer of enzymes and micro-organisms, Novonesis generates sales primarily from the cleaning and household products industry (28.5%) and bioenergy (24.8%), with significant contributions from food and human health (22.1%) and agriculture (11.8%). Geographically, North America accounts for 33.9% of sales, followed by Europe-Middle East-Africa (33.5%) and Asia-Pacific (18.5%).
UBS has lowered its target price for Novonesis A/S to DKK 455 while maintaining a neutral rating. The company, a leader in enzyme and microorganism production, generates net sales primarily from cleaning products (28.5%), bioenergy (24.8%), and the food industry (22.1%), with significant revenue from North America (33.9%) and Europe/Middle East/Africa (33.5%).
UBS has reduced its target price for H Lundbeck A/S to DKK 45 from DKK 49, maintaining a neutral stance on the company. Lundbeck, based in Denmark, specializes in pharmaceuticals for brain diseases, with a portfolio that includes treatments for conditions such as depression, Alzheimer's, and Parkinson's.
UBS has reduced its target price for Lundbeck to DKK 45 from DKK 49 while maintaining a neutral stance on the company. Lundbeck A/S, a Danish pharmaceutical firm, specializes in developing treatments for brain disorders, including Alzheimer's, depression, and Parkinson's disease, with a diverse product portfolio.
Danish Krone
Currency
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
analysts update recommendations and price targets for key european stocks
British Pound Sterling
Danish Krone
Swiss Franc
Euro
United States Dollar
Ørsted A/S
JD Sports Fashion Plc
Axon Partners Group, S.A.
Teleperformance SE
Assystem S.A.
OVH Groupe
Transgene SA
Just Eat Takeaway.com N.V.
Swiss Re AG
Edenred SE
HelloFresh SE
La Francaise des Jeux SA
Vivendi SE
UBS Group AG
Orange S.A.
Bureau Veritas SA
Geberit AG
BELIMO Holding AG
Watches of Switzerland Group PLC
JCDecaux SE
Michelin
Adecco Group AG
Air France-KLM
argenx SE
SGS SA
Cargotec Oyj
Deliveroo plc
Gecina
Eurofins Scientific S.E. A
Bufab AB
Delivery Hero SE
bioMérieux
Sika AG
FRA
DEU
CHE
GBR
DNK
USA
SWE
Show more
08:48 15.01.2025
ubs maintains buy rating on novo nordisk with 19 percent upside potential
10:56 14.01.2025
ubs upgrades novo nordisk to buy amid positive glp-1 demand outlook
10:38 08.01.2025
novo nordisk faces stock plunge after disappointing results for obesity drug
Danish Krone
Catalent, Inc.
Novo Nordisk A/S
Eli Lilly and Company
DNK
Florent Cespedes
Emmanuel Papadakis
Jo Walton
Peter Welford
Show more
15:35 20.12.2024
ubs maintains neutral rating on novo nordisk amid disappointing weight loss data
15:17 20.12.2024
UBS Adjusts Novonesis Target Price Amid Diverse Global Market Presence
09:59 18.12.2024
ubs lowers novonesis target price to dkk 455 maintains neutral stance
09:59 18.12.2024
ubs lowers novonesis target price while maintaining neutral outlook
09:59 18.12.2024
UBS Lowers Lundbeck Target Price Amid Ongoing Pharmaceutical Developments
09:55 17.12.2024
UBS Cuts Lundbeck Target Price to DKK 45 Maintains Neutral Rating
09:55 17.12.2024
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Banking Regulations
Finance Mergers & Acquisitions
Global Financial Events
Retail and Consumer Goods
CEO Changes
Central Bank Actions
GDP Growth & Recession Forecasts
Global Trade Developments
Market Analysis and Predictions
Industry Mergers & Acquisitions
Financial Scams and Security
Inflation and Monetary Impact
Government Policies
Government Economic Policies
Supply Chain Management
Startups & Entrepreneurship
Workplace Trends
Countries:
Companies:
The Goldman Sachs Group, Inc.
JPMorgan Chase & Co.
Tesla, Inc.
Apple Inc.
Barclays PLC
Bank of America Corporation
Wells Fargo & Company
Citigroup Inc.
Deutsche Bank Money Market PP
Morgan Stanley
Huawei Technologies CO. Ltd.
Lloyds Banking Group plc
Microsoft Corporation
Credit Suisse Strategic Income I
NVIDIA Corporation
Amazon.com, Inc.
AXA SA
Safran SA
Banco Santander, S.A.
Novartis AG
Currencies:
United States Dollar
Euro
Chinese Yuan
British Pound Sterling
Swiss Franc
Japanese Yen
Indian Rupee
Russian Ruble
Australian Dollar
Canadian Dollar
United Arab Emirates Dirham
Indonesian Rupiah
Saudi Riyal
South Korean Won
Danish Krone
Offshore Chinese Yuan
Turkish Lira
Hong Kong Dollar
Mexican Peso
Malaysian Ringgit
People: